Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
Download search resultsDownload the search results for:
"HIV Preventive Vaccine" [CONDITION] (130 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults
Condition: HIV Infections
Interventions: Biological: EP HIV-1043;   Biological: EP HIV-1090
3 Active, not recruiting Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: rAd35 Env A;   Biological: rAd5 Env A;   Biological: rAd5 Env B
4 Completed Safety of and Immune Response to a DNA HIV Vaccine Followed By an Adenoviral Vector HIV Vaccine in Healthy Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA016-00-VP;   Biological: VRC-HIVADV014-00-VP;   Biological: VRC-HIVDNA016-00-VP placebo;   Biological: VRC-HIVADV014-00-VP placebo
5 Completed Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
6 Unknown  Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9
7 Completed Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
8 Completed Screening Protocol for HIV Vaccine Studies
Conditions: HIV Seronegativity;   HIV Infections
Intervention:
9 Completed Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
Condition: HIV Infections
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: gp160 MN/LAI-2;   Biological: ALVAC(1)120(B,MN)GNP (vCP1433);   Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65)
10 Active, not recruiting Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA-016-00-VP;   Biological: VRCHIVADV014-00-VP
11 Completed Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: MRKAd5 HIV-1 gag/pol/nef
12 Active, not recruiting Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
Condition: HIV Infections
Interventions: Biological: DNA Vaccine;   Biological: DNA Vaccine placebo;   Biological: rAd35;   Biological: rAd35 placebo;   Biological: rAd5;   Biological: rAd5 placebo
13 Completed A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection
Condition: HIV Infections
Interventions: Biological: MVA-B;   Biological: Placebo
14 Completed Early Immune Responses to Vaccination - A Substudy to HVTN 205
Condition: HIV Infections
Interventions: Biological: JS7 DNA vaccine;   Biological: MVA/HIV62 vaccine
15 Completed Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65)
16 Completed A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART
Condition: HIV Infection
Interventions: Drug: Vaccination;   Drug: Placebo
17 Active, not recruiting Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: DNA plasmid vaccine;   Biological: Recombinant adenoviral serotype 5 (rAD5) vector vaccine;   Biological: DNA vaccine placebo;   Biological: HIV-1 recombinant adenovirus vaccine placebo
18 Completed A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.
Condition: HIV Infections
Interventions: Biological: MN rgp120/HIV-1;   Biological: TBC-3B Vaccine
19 Completed Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein
Condition: HIV Infections
Intervention: Biological: Biologically active recombinant Tat protein
20 Completed A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects
Condition: HIV Infections
Intervention: Biological: HIV-1 Peptide Vaccine, Microparticulate Monovalent

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years